Imagine a world where millions of people battling chronic hepatitis B could finally see a path to freedom from this relentless liver-damaging virus—sounds like the plot of a medical thriller, right? But here's the real story unfolding: AusperBio has just unveiled groundbreaking 48-week Phase II data on their innovative treatment, AHB-137, at the prestigious AASLD 2025 conference, sparking excitement and debate in the medical community about what this means for patients worldwide.
Let me break this down for you in a way that's easy to follow, even if you're new to the world of liver diseases. Chronic hepatitis B (CHB) is a serious infection caused by the hepatitis B virus (HBV), which attacks the liver and can lead to cirrhosis, cancer, or other life-threatening complications. Many patients manage it with nucleos(t)ide analogs (NAs)—that's a type of antiviral medication that keeps the virus in check but often requires lifelong use. For those who are HBeAg-negative (a marker indicating the virus isn't replicating as aggressively), finding a way to stop treatment and stay virus-free is a big deal.
AusperBio Therapeutics, Inc., and Ausper Biopharma Co., Ltd.—collectively known as AusperBio, a cutting-edge biotech firm focused on gene-based therapies—shared these promising results from a late-breaking poster session at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases from November 7–11 in Washington, D.C. They pooled data from two randomized Phase II trials (Phase IIa, NCT06115993, and Phase IIb, NCT06550128), both targeting HBeAg-negative CHB patients already on NA therapy.
What stood out? AHB-137 delivered strong, lasting antiviral effects even 24 weeks after treatment ended (by Week 48). Think sustained responses like complete response—where hepatitis B surface antigen (HBsAg) levels drop below 0.05 IU/mL and viral DNA becomes undetectable—and partial response, with HBsAg under 10 IU/mL and DNA undetectable. The 300 mg dose over 24 weeks showed the best results, working consistently no matter the patient's starting HBsAg levels. Plus, it was well-tolerated, with no unexpected safety issues popping up during the follow-up period. This data paves the way for AHB-137's progress toward a functional cure for CHB, meaning the virus is controlled enough that patients can stop treatment and live without constant monitoring—though it's not a full eradication.
And this is the part most people miss: The presentation details dive deep into the science. Titled 'High Proportion of Participants Achieved Sustained Complete Response 24 Weeks After End of AHB-137 Treatment in HBeAg Negative Chronic Hepatitis B Participants on NA Therapy: Pooled Analysis of Two Phase 2 Studies in China,' it was presented under Publication Number 5022 on November 8, 2025, from 8:00 am to 5:00 pm ET in the Saturday Late Breaking Posters session (numbers 5019-5025). The authors include a stellar team: Yanhua Ding, Xieer Liang, Yanhang Gao, Dachuan Cai, Xian Yu, Youwen Tan, Haibing Gao, Jidong Jia, Hong Ren, Chongyuan Xu, Shan Zhong, Zhihong Liu, Hong Ma, Wen Wang, Xingbei Zhou, Huaxi Ma, Yi Yang, Xinrui Wang, Fei Kong, Lidan Wang, Di Zhao, Xiao Qiu, Chen Yang, Yeming Pan, Hao Wang, Miao Wang, Chris Yang, Guofeng Cheng, Jinlin Hou, and Junqi Niu. You can check out the full program and abstracts on the AASLD website at https://www.aasld.org/the-liver-meeting.
But here's where it gets controversial: Is a functional cure truly the holy grail for hepatitis B, or are we settling for less by not pursuing total virus elimination? Some experts argue that even undetectable levels might hide risks of reactivation, sparking debates about long-term outcomes. AHB-137 itself is a game-changer—a novel unconjugated antisense oligonucleotide (ASO) crafted with AusperBio's proprietary Med-Oligo™ technology. For beginners, ASOs are like tiny molecular scissors that target specific RNA to block virus production. This dual-mechanism approach has shown impressive preclinical and early clinical results, presented at global events like EASL (in 2023, 2024, and 2025), AASLD (2024), and APASL (2025). It's wrapped up a global Phase I trial and is now in multiple Phase II studies plus a Phase III in China, all part of a coordinated worldwide strategy aimed at that elusive functional cure for HBV.
About AusperBio: This clinical-stage biopharma powerhouse operates in the U.S. and China, pioneering oligonucleotide therapies and targeted delivery systems. Their Med-Oligo™ platform revolutionizes ASO treatments by improving design and adding efficient delivery methods, opening doors to tackle not just viral infections like HBV, but also metabolic issues, genetic disorders, and immune conditions. Curious for more? Head to their site at www.ausperbio.com.
For media inquiries, reach out via email at [emailprotected]. Investors, give them a call at 650-888-1756 (U.S.) or email [emailprotected].
SOURCE: AusperBio Therapeutics Inc.
What do you think? Does this shift in hepatitis B treatment excite you as a potential breakthrough, or do you worry about the unknowns in achieving a full cure? Is relying on NA therapy beforehand a smart move, or could it complicate things? Share your thoughts in the comments—we'd love to hear your take and spark a discussion!
